Login to Your Account



ZymoGenetics Narrows Focus Again; Licenses Anti-IL21 mAb

By Trista Morrison


Wednesday, December 9, 2009
ZymoGenetics Inc. continued its transformation from a discovery engine to a development and sales organization, this time out-licensing its preclinical anti-IL21 antibody to former parent company Novo Nordisk A/S. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription